Table 3.
Uni- and multivariable generalized estimating equations (GEE) logistic regression model for 30-day mortality.
| Variables | OR (95%-CI) |
|---|---|
| Univariable analysis | |
| Age | 1.071 (1.063−1.080) |
| BMI | 0.976 (0.946−1.008) |
| Sex (male) | 0.780 (0.554−1.097) |
| Any comorbidities | 1.797 (1.133−2.846) |
| Cardiovascular disease | 1.310 (0.583−1.811) |
| Diabetes mellitus | 1.749 (1.218−2.512) |
| Asthma | 1.001 (0.441−2.270) |
| COPD | 1.564 (0.806−3.031) |
| Rheumatological disease | 1.305 (0.710−2.401) |
| Solid organ malignancy | 0.995 (0.650−1.523) |
| Chronic kidney disease | 2.568 (1.132−5.824) |
| Thyroid disease | 1.795 (1.021−3.155) |
| Any EORTC/MSGERC criterium [8] | 2.273 (1.454−3.550) |
| APACHE IV at ICU admission | 1.011 (0.999−1.022) |
| SOFA at ICU admission | 1.034 (0.953−1.122) |
| Remdesivir* | 1.531 (1.034−2.268) |
| Corticosteroids* | 0.519 (0.411−0.656) |
| Tocilizumab* | 0.614 (0.405−0.931) |
| Corticosteroids and tocilizumab* | 0.628 (0.419−0.944) |
| Pre-emptive screening† | 1.578 (0.999−2.489) |
| Multivariable analysis | |
| Age | 1.073 (1.060−1.085) |
| Diabetes mellitus | 1.415 (0.953−2.100) |
| Chronic kidney disease | 1.728 (0.756−3.955) |
| Any EORTC/MSGERC criterium [8] | 2.509 (1.468−4.284) |
| Remdesivir* | 1.365 (0.876−2.125) |
| Corticosteroids* | 0.492 (0.319−0.757) |
| Tocilizumab* | 0.802 (0.495−1.298) |
*Treatment for COVID-19, †Medical centres that pre-emptively screened for CAPA: Aspergillus diagnostics performed in all patients with COVID-19 admitted to the ICU irrespective if there was a suspicion of CAPA.
OR: odds ratio, 95%-CI: 95% confidence interval.